395 related articles for article (PubMed ID: 26288093)
21. Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Benhamou Y; Fleury H; Trimoulet P; Pellegrin I; Urbinelli R; Katlama C; Rozenbaum W; Le Teuff G; Trylesinski A; Piketty C;
Hepatology; 2006 Mar; 43(3):548-55. PubMed ID: 16496322
[TBL] [Abstract][Full Text] [Related]
22. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
[TBL] [Abstract][Full Text] [Related]
23. Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Price H; Dunn D; Pillay D; Bani-Sadr F; de Vries-Sluijs T; Jain MK; Kuzushita N; Mauss S; Núñez M; Nüesch R; Peters M; Reiberger T; Stephan C; Tan L; Gilson R
PLoS One; 2013; 8(7):e68152. PubMed ID: 23874527
[TBL] [Abstract][Full Text] [Related]
24. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Huang YS; Sun HY; Chang SY; Chuang YC; Cheng A; Huang SH; Huang YC; Chen GJ; Lin KY; Su YC; Liu WC; Hung CC
Hepatol Int; 2019 Jul; 13(4):431-439. PubMed ID: 31177505
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
[TBL] [Abstract][Full Text] [Related]
26. An evaluation of hepatitis B virus diagnostic methods and responses to antiretroviral therapy among HIV-infected women in Thailand.
Peters PJ; McNicholl JM; Raengsakulrach B; Wasinrapee P; Mueanpai F; Ratanasuwan W; Intalapaporn P; Drobeniuc J; Ramachandran S; Thai H; Xia GL; Kamili S; Khudyakov Y; Weidle PJ; Teo CG; McConnell MS
J Int Assoc Provid AIDS Care; 2013; 12(5):349-53. PubMed ID: 23792710
[TBL] [Abstract][Full Text] [Related]
27. Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression.
Lartey M; Ganu VJ; Tachi K; Yang H; Anderson PL; Langaee T; Ojewale O; Boamah I; Obo-Akwa A; Antwi K; Bushman LR; Ellison L; Kwara A
AIDS; 2024 Mar; 38(3):351-362. PubMed ID: 37861682
[TBL] [Abstract][Full Text] [Related]
28. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
29. Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Khamduang W; Gaudy-Graffin C; Ngo-Giang-Huong N; Jourdain G; Moreau A; Luekamlung N; Halue G; Buranawanitchakorn Y; Kunkongkapan S; Buranabanjasatean S; Lallemant M; Sirirungsi W; Goudeau A;
PLoS One; 2012; 7(7):e42184. PubMed ID: 22860080
[TBL] [Abstract][Full Text] [Related]
30. New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Dunn D; Price H; Vudriko T; Kityo C; Musoro G; Hakim J; Gilks C; Kaleebu P; Pillay D; Gilson R;
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):98-103. PubMed ID: 33306565
[TBL] [Abstract][Full Text] [Related]
31. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Matthews GV; Bartholomeusz A; Locarnini S; Ayres A; Sasaduesz J; Seaberg E; Cooper DA; Lewin S; Dore GJ; Thio CL
AIDS; 2006 Apr; 20(6):863-70. PubMed ID: 16549970
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Ingiliz P; Valantin MA; Thibault V; Duvivier C; Dominguez S; Katlama C; Poynard T; Benhamou Y
Antivir Ther; 2008; 13(7):895-900. PubMed ID: 19043923
[TBL] [Abstract][Full Text] [Related]
34. Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy.
Day SL; Odem-Davis K; Mandaliya KN; Jerome KR; Cook L; Masese LN; Scott J; Kim HN; Graham SM; McClelland RS
PLoS One; 2013; 8(3):e59346. PubMed ID: 23527168
[TBL] [Abstract][Full Text] [Related]
35. Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Núñez M; Ramos B; Díaz-Pollán B; Camino N; Martín-Carbonero L; Barreiro P; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2006 Sep; 22(9):842-8. PubMed ID: 16989608
[TBL] [Abstract][Full Text] [Related]
36. Brief Report: Relationship Between ABCC4 SNPs and Hepatitis B Virus Suppression During Tenofovir-Containing Antiretroviral Therapy in Patients With HIV/HBV Coinfection.
Archampong T; Ojewale O; Bears K; Chen Y; Lartey M; Sagoe KW; Obo-Akwa A; Gong Y; Langaee T; Kwara A
J Acquir Immune Defic Syndr; 2019 Dec; 82(4):421-425. PubMed ID: 31335591
[TBL] [Abstract][Full Text] [Related]
37. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
Tuma P; Pineda JA; Labarga P; Vidal F; Rodriguez C; Poveda E; Santos J; Gonzalez-García J; Sobrino P; Tural C; Soriano V;
Antivir Ther; 2011; 16(4):585-9. PubMed ID: 21685546
[TBL] [Abstract][Full Text] [Related]
38. Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
Archampong TN; Lartey M; Sagoe KW; Obo-Akwa A; Kenu E; Gillani FS; Yang H; Boamah I; Flanigan T; Kwara A
BMC Infect Dis; 2016 Jan; 16():14. PubMed ID: 26759172
[TBL] [Abstract][Full Text] [Related]
39. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Gatanaga H; Hayashida T; Tanuma J; Oka S
Clin Infect Dis; 2013 Jun; 56(12):1812-9. PubMed ID: 23487374
[TBL] [Abstract][Full Text] [Related]
40. Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR; Ribeiro RM; Avihingsanon A; Bowden S; Matthews G; Marks P; Locarnini SA; Ruxrungtham K; Perelson AS; Dore GJ
Hepatology; 2009 Apr; 49(4):1113-21. PubMed ID: 19115219
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
